Some collaborations change the face of treatment scenario, and this collaboration is one example of that. An immunologist collaborated with an oncologist to help fight the immunologist’s stepmother fight cancer, and turned the face of transformative therapy. The discovery is of a new class of drugs that help in bypassing a molecular break that stops the immune system from attacking tumors. The main problem in cancer is that patients immunotherapy doesn’t always work. Here, the researchers identified a unique type of immune-system cell that helps in predicting whether patients will respond to one of the medicines or not—significantly sorting out patients that can positively benefit from the therapy. This discovery is based on the analysis of 40 patients, whose cancer is treated with Keytruda, a checkpoint inhibitor from Merck & Co., which targets an immune-system brake called PD-1.
DelveInsight Blog
Related Article
The Rise of TCR Therapy: A Beacon of Hope in Cancer Treatment
T-cell receptor (TCR)-dependent treatment involves modified immune cells aimed at attacking particular tumor indicators. This treatment approach necessitates a systematic procedure including patient evaluation (e.g., for HLA-A*02:01 and precise tumor markers), collecting immune cells, creating the altered TCR produ...
Find MoreHarmony in Treatment: GOLCA (golcadomide) Reveals Favorable Safety Profile and Seamless Integration with R-CHOP for Untreated Aggressive B-Cell Lymphoma
Date of Abstract presentation11th December 2023IndicationsAggressive B-cell lymphoma (a-BCL)Abstract Number4459Abstract typePoster Approximately 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL) experience relapse following initial treatment with rituximab, cyclophosphamide, doxorubicin, vincr...
Find MoreALLO-647 Integration in Lymphodepletion: Paving the Way for Enduring Responses and Safe CAR T cell Therapy Advancements
Date of Abstract presentation9th December 2023IndicationsRelapsed/Refractory (r/r) Large B-Cell and Follicular LymphomasAbstract Number2095Abstract typePoster Despite the rising clinical fascination with autologous CAR T-cell therapies for hematologic malignancies and their noteworthy achievements, persistent ch...
Find MoreEditor's Pick
Newsletter/Whitepaper
Recent Article
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.